<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537794</url>
  </required_header>
  <id_info>
    <org_study_id>TPET-01</org_study_id>
    <nct_id>NCT03537794</nct_id>
  </id_info>
  <brief_title>Characterizing Dopamine Receptor Binding in Treatment Resistant Depression</brief_title>
  <official_title>Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is estimated that 30% of individuals with Major Depressive Disorder (MDD) fail to respond&#xD;
      to conventional antidepressant medication which accounts for over 1 million Canadians in&#xD;
      their lifetime. Treatment resistant depression (TRD) patients also have greater psychiatric&#xD;
      and medical comorbidity, poorer quality of life and increased suicidal ideation. Yet, there&#xD;
      are few treatment strategies available to target TRD and there is a significant lack of&#xD;
      evidence about how TRD differs from treatment-responsive depression. This proposal represents&#xD;
      the first study to elucidate the neurobiology of TRD with a focus on dopamine receptor&#xD;
      function throughout the brain, in order to inform treatment development and clinical&#xD;
      characterization of TRD.The ultimate goal of this unique study is to characterize striatal&#xD;
      and extrastriatal dopamine D2 and D3 receptor binding potential in patients with TRD,&#xD;
      non-resistant MDD and healthy controls. The primary hypothesis is that TRD patients will&#xD;
      exhibit greater D2/D3 receptor binding potential compared to non-TRD patients in the&#xD;
      following regions of interest: dorsolateral prefrontal cortex, orbitofrontal cortex, and&#xD;
      ventral striatum. Secondarily, non-TRD patients will also demonstrate increased binding&#xD;
      potential compared to healthy controls in the same brain regions. Whole brain analyses will&#xD;
      allow us to take an exploratory approach to other brain regions that may differentiate TRD&#xD;
      from non-TRD patients. Participants will be assessed at St. Michael's Hospital (SMH) and the&#xD;
      Centre for Addiction and Mental Health (CAMH), which are within a 10 minute driving distance&#xD;
      of each other. There will be 3 study visits following written informed consent. Eligibility&#xD;
      will be confirmed at a screening visit at SMH where demographic information, including age,&#xD;
      sex, education, and medication history will be obtained, as well as the administration of a&#xD;
      structured Mini-International Neuropsychiatric Interview (MINI) for Diagnostic and&#xD;
      Statistical Manual of Mental Disorders (DSM-5) Axis I diagnoses (Sheehan et al, 2015), and an&#xD;
      HRSD-17. Within two weeks of the screening visit, participants will undergo a structural&#xD;
      magnetic resonance imaging (MRI) scan at SMH prior to the positron-emission tomography (PET)&#xD;
      scan at CAMH. The order of the PHNO scans will be counterbalanced.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dopamine potential</measure>
    <time_frame>3 years</time_frame>
    <description>TRD patients exhibit greater D2/D3 receptor binding potential</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Treatment Resistant Depression</arm_group_label>
    <description>Unmedicated Individuals with Treatment Resistant Depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Depressive Disorder</arm_group_label>
    <description>Unmedicated Individuals with Major Depressive Disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>healthy controls with no previous psychiatric disorders</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET scans</intervention_name>
    <description>PET scans and PHNO scans</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Major Depressive Disorder</arm_group_label>
    <arm_group_label>Treatment Resistant Depression</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from clinics at St. Michael's Hospital and the Centre for&#xD;
        Addiction and Mental Health as well as from research programs at the two sites, which have&#xD;
        ongoing MDD clinical trials where patients are required to be unmedicated prior to&#xD;
        initiating treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Key inclusion criteria for the MDD patients:&#xD;
&#xD;
               -  DSM-5 criteria for a Major Depressive Episode (MDE) within a MDD, confirmed&#xD;
                  through MINI diagnosis (Sheehan et al, 2015)&#xD;
&#xD;
               -  Age between 25 and 55 years&#xD;
&#xD;
               -  Hamilton Depression Rating Scale - 17 item (HRSD-17; Hamilton, 1960) &gt; 14&#xD;
                  (moderate to severe symptoms)&#xD;
&#xD;
               -  Free of psychotropic medications for at least 5 half-lives before PET scanning&#xD;
&#xD;
               -  Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)&#xD;
&#xD;
               -  For non-resistant patients: Previous history of response to an antidepressant, in&#xD;
                  order to increase signal to noise between resistant and non-resistant patients&#xD;
&#xD;
        Key inclusion criteria for the Healthy Controls:&#xD;
&#xD;
          -  Ages between 25 and 55 years&#xD;
&#xD;
          -  Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Key exclusion criteria for the MDD patients:&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Medical condition requiring immediate investigation or treatment&#xD;
&#xD;
          -  Recent (&lt; 6 months)/current history of drug abuse/dependence&#xD;
&#xD;
          -  Lifetime history of psychosis, other Axis I comorbidities are allowable&#xD;
&#xD;
          -  Use of any psychotropic use within 5 half-lives before the PET scanning&#xD;
&#xD;
          -  For non-resistant patients: Failure of &gt; 2 antidepressant treatments of adequate dose&#xD;
             and duration for current MDE.&#xD;
&#xD;
        Key exclusion criteria for the Healthy Controls:&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Medical condition requiring immediate investigation or treatment&#xD;
&#xD;
          -  Lifetime history of any psychiatric disorder&#xD;
&#xD;
          -  Lifetime history of receiving an antidepressant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sakina Rizvi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sakina Rizvi, PhD</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>6489</phone_ext>
    <email>rizvis@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariel Graff-Guerrero, MD, PhD</last_name>
    <phone>416-535-850</phone>
    <phone_ext>34834</phone_ext>
    <email>ariel.graff@camh.ca</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

